中华肝脏病杂志最新文献

{"title":"[Expert recommendations on screening, testing and management for hepatitis B virus infection in adults].","authors":"","doi":"10.3760/cma.j.cn501113-20240723-00340","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240723-00340","url":null,"abstract":"<p><p>The prevalence of hepatitis B represents a significant public health concern with a heavy disease burden. In China, there is still a big gap between the current diagnosis and treatment rates of hepatitis B and the goal of eliminating viral hepatitis as a public health threat by 2030 set by the World Health Organization (WHO). In order to achieve the WHO goal and the goal of 2030 Healthy China Outline, the Chinese Preventive Medicine Association organized domestic experts in the fields of clinical medicine, public health and clinical laboratory medicine to develop the Expert Recommendations on Screening, Testing and Management for Hepatitis B Virus Infection in Adults after several rounds of discussion based on comprehensive review of relevant domestic and international guidelines and literatures, the purpose is to facilitate universal screening of hepatitis B virus(HBV)infection in adults and provide practical guidance on disease assessment, treatment and long-term follow-up management of people infected with HBV and vaccination for people susceptible to HBV infection,thus promoting the elimination of the threat of hepatitis B.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"718-725"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[SUV3 knockdown inhibits proliferation, migration, and invasion of hepatocellular carcinoma cells and induces PD-L1 expression].","authors":"J H Zhang, X Wu, T T Wang, Z S Wang","doi":"10.3760/cma.j.cn501113-20240407-00176","DOIUrl":"10.3760/cma.j.cn501113-20240407-00176","url":null,"abstract":"<p><p><b>Objective:</b> To study the SUV3 gene role during the process of occurrence and advancement of hepatocellular carcinom. <b>Methods:</b> The The differences in SUV3 expression between hepatocellular carcinoma tissues and normal liver tissues were compared by analyzing transcriptome sequencing data from TCGA and GTEx databases. SUV3 knockdown in different hepatocellular carcinoma cells was performed using RNA interference technology. Overexpression vectors were constructed to overexpress SUV3 in different hepatocellular carcinoma cells. The SUV3 regulatory effect was studied on proliferation, migration, and invasion of hepatocellular carcinoma cells. A subcellular fraction isolation approach was used to investigate whether SUV3 knockdown resulted in the release of mitochondrial DNA into the cytoplasm. Quantitative reverse transcription PCR was applied to investigate whether SUV3 knockdown affected PD-L1 expression. The two groups were compared using a two-tailed <i>t</i>-test. <b>Results:</b> The TCGA database analysis revealed that SUV3 expression was higher in hepatocellular carcinoma tissues than in normal liver tissues, and the prognosis of patients with high SUV3 expression in hepatocellular carcinoma tissues was poor. The quantitative RT-PCR results showed that SUV3 expression was higher in hepatocellular carcinoma tissues than that in paracancerous liver tissue. The MTS assay showed that with SUV3 knockdown, the proliferation rate was significantly lower in hepatocellular carcinoma cells than that of the control hepatocellular carcinoma cells (<i>P</i><0.01). The proliferation rate was significantly higher in SUV3-overexpressed hepatocellular carcinoma cells than that of control hepatocellular carcinoma cells (<i>P</i><0.01). Cell scratch assay and cell migration and invasion assay showed that SUV3 knockdown inhibited the migration and invasion of hepatocellular carcinoma cells (<i>P</i><0.01), while SUV3 overexpression promoted the migration and invasion of hepatocellular carcinoma cells (<i>P</i><0.05). SUV3 Knockdown led to a decrease in the overall level of mtDNA (<i>P</i><0.01) in accompanied by an increase in mtDNA level in the cytoplasm (<i>P</i><0.01), indicating that SUV3 knockdown led to mitochondrial DNA leakage into the cytoplasm. SUV3 knockdown resulted in elevated PD-L1 expression (<i>P</i><0.001), and overexpression of TREX1 in SUV3 knockdown cells decreased mtDNA levels in the cytoplasm and inhibited SUV3 knockdown, resulting in elevated PD-L1 expression, indicating that SUV3 knockdown induced PD-L1 expression by increasing cytoplasmic DNA levels. <b>Conclusions:</b> The SUV3 gene may play an oncogenic function in hepatocellular carcinoma cells.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"734-743"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of the long-term prognosis of transjugular intrahepatic portosystemic shunt treatment for esophagogastric variceal hemorrhage concomitant with sarcopenia in cirrhotic patients].","authors":"X X Wang, M Zhang, X C Yin, B Gao, L L Gu, W Li, J Q Xiao, S Zhang, W Zhang, X Zhang, X P Zou, L Wang, Y Z Zhuge, F Zhang","doi":"10.3760/cma.j.cn501113-20240414-00203","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240414-00203","url":null,"abstract":"<p><p><b>Objective:</b> To explore whether transjugular intrahepatic portosystemic shunt (TIPS) can improve the prognosis of esophagogastric variceal bleeding (EGVB) combined with sarcopenia in cirrhotic patients. <b>Methods:</b> A retrospective cohort study was performed. A total of 464 cases with cirrhotic EGVB who received standard or TIPS treatment between January 2017 and December 2019 were selected. Regular follow-up was performed for the long-term after treatment. The primary outcome was transplantation-free survival. The secondary endpoints were rebleeding and overt hepatic encephalopathy (OHE). The obtained data were statistically analyzed. The <i>t</i>-test and Wilcoxon rank-sum test were used to compare continuous variables between groups. The <i>χ</i>² test, or Fisher's exact probability test, was used to compare categorical variables between groups. <b>Results:</b> The age of the included patients was 55.27±13.86 years, and 286 cases were male. There were 203 cases of combined sarcopenia and 261 cases of non-combined sarcopenia. The median follow-up period was 43 months. The two groups had no statistically significant difference in follow-up time. There was no statistically significant difference in transplant-free survival between the TIPS group and the standard treatment group in the overall cohort (<i>HR</i>=1.31, 95%<i>CI</i>: 0.97-1.78, <i>P</i>=0.08). The TIPS patient group with cirrhosis combined with sarcopenia had longer transplant-free survival (median survival: 47.76 vs. 52.45, <i>χ</i>²=4.09; <i>HR</i>=1.55, 95<i>CI</i>: 1.01~2.38, <i>P</i>=0.04). There was no statistically significant difference in transplant-free survival between the two kinds of treatments for patients without sarcopenia (<i>HR</i>=1.22, 95%<i>CI</i>: 0.78~1.88, <i>P</i>=0.39). Rebleeding time was prolonged in TIPS patients with or without sarcopenia combination (patients without combined sarcopenia: median rebleeding time: 39.48 vs. 53.61, <i>χ</i>²=18.68; <i>R</i>=2.47, 95<i>CI</i>: 1.67~3.65, <i>P</i><0.01; patients with sarcopenia: median rebleeding time: 39.91 vs. 50.68, <i>χ</i>²=12.36; <i>HR</i>=2.20, 95<i>CI</i>: 1.42~3.40, <i>P</i><0.01). TIPS patients had an increased 1-year OHE incidence rate compared to the standard treatment group (sarcopenia patients: 6.93% vs. 16.67%, <i>χ</i>²=3.87, <i>P</i>=0.049; patients without sarcopenia combination: 2.19% vs. 9.68%, <i>χ</i>²=8.85, <i>P</i>=0.01). There was no statistically significant difference in the long-term OHE incidence rate between the two kinds of treatment groups (<i>P</i>>0.05). <b>Conclusion:</b> TIPS can significantly prolong transplant-free survival compared to standard treatment as a secondary prevention of EGVB concomitant with sarcopenia in patients with cirrhosis. However, its advantage is not prominent for patients with cirrhosis in EGVB without sarcopenia.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"744-752"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application and prospects of magnetic resonance imaging techniques in the diagnosis and evaluation of hepatocellular carcinoma].","authors":"J H Jiang, D W Yang, Y X Wang, X Dong, Z H Yang","doi":"10.3760/cma.j.cn501113-20240607-00287","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240607-00287","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. MRI has become an important imaging method for non-invasive diagnosis and evaluation of HCC in clinics because of its advantageous aspects, such as its non-radiative nature, superior detection, and qualitative accuracy over CT and ultrasound. Various MRI techniques, including hepatobiliary-specific contrast agents, magnetic resonance elastography, diffusion-weighted imaging, and others, can diagnose HCC or evaluate its malignant biological behavior from different dimensions such as blood supply, cell function, tissue hardness, and water molecule diffusion. This article introduces the current status and prospects of various MRI techniques for HCC diagnosis and evaluation.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"695-701"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparative study of ultra-high field diffusion-weighted MRI imaging between hepatocellular carcinoma and paracancerous, distant cancerous, and background liver tissues].","authors":"T Yuan, B G Tan, J Ou, Y P Wu, T W Chen","doi":"10.3760/cma.j.cn501113-20240530-00276","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240530-00276","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the differences in multi-b-value apparent diffusion coefficient (ADC) and exponential apparent diffusion coefficient (eADC) between hepatocellular carcinoma (HCC) and paracancerous liver tissue, distant cancerous liver tissue, and background liver tissues by ultra-high field 3.0T diffusion-weighted (DWI) MRI imaging. &lt;b&gt;Methods:&lt;/b&gt; Sixty-eight consecutive HCC cases confirmed by surgical pathology from January 2018 to October 2021 were enrolled and divided into a cirrhosis (&lt;i&gt;n&lt;/i&gt;=39) and a non-cirrhosis group (&lt;i&gt;n&lt;/i&gt;=29) according to the presence or absence of cirrhosis.The average ADC and eADC of liver tissues of paracancerous (including proximal and distal), distant cancerous, and background were measured by DWI images with diffusion sensitivity factors (b) of 50, 100, 400, 600 s/mm&lt;sup&gt;2&lt;/sup&gt;, and 1 000 s/mm&lt;sup&gt;2&lt;/sup&gt;, respectively. The Kruskal-Wallis H test and Bonferroni method were used to test the differences between the measured values of the five tissues. The statistical differences were used to evaluate the diagnostic efficacy of the five tissues by parametric receiver operating characteristic (ROC) curve and area under the curve (AUC). &lt;b&gt;Results:&lt;/b&gt; The comparison of average ADC and eADC among five types of tissues in the liver cirrhosis group showed that the average ADC and eADC measured at b values of 50, 100, 400, and 600 s/mm&lt;sup&gt;2&lt;/sup&gt; had statistically significant differences (adjusted &lt;i&gt;P&lt;/i&gt;&lt;0.005) between cancerous and proximal paracancerous, distal paracancerous, distant cancerous, and background liver tissue, as well as the average ADC measured at b=1 000 s/mm&lt;sup&gt;2&lt;/sup&gt; between cancerous and proximal paracancerous tissue. The average ADC and eADC in the non-cirrhosis group had statistically significant differences (adjusted &lt;i&gt;P&lt;/i&gt;&lt;0.005) between cancerous and proximal paracancerous, distant paracancerous, distant cancerous, and background liver tissue measured at b values of 50, 100, and 400 s/mm&lt;sup&gt;2&lt;/sup&gt;, respectively. The average ADC and eADC measured at b=600 s/mm&lt;sup&gt;2&lt;/sup&gt; showed statistically significant differences (adjusted &lt;i&gt;P&lt;/i&gt;&lt;0.005) between cancerous and proximal paracancerous, distal paracancerous, and distant cancerous liver tissue, as well as the average ADC measured at b=1 000 s/mm&lt;sup&gt;2&lt;/sup&gt; between cancerous and distal paracancerous, and distant cancerous liver tissue. The average ADC and eADC in the cirrhosis group had no statistically significant difference between the proximal paracancerous and the distant cancerous, as well as the background liver tissue measured at b-values of 50, 100, 400, 600, and 1 000 s/mm&lt;sup&gt;2&lt;/sup&gt;, respectively (adjusted &lt;i&gt;P&lt;/i&gt;&gt;0.005), while there were statistically significant differences (adjusted &lt;i&gt;P&lt;/i&gt;&lt;0.005) in the average ADC values in the non-cirrhosis group between the proximal paracancerous and the distant paracancerous and background liver tissues at b=50 s/mm&lt;sup&gt;2&lt;/sup&gt;, as well as the average ADC an","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 8","pages":"726-733"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Comparison of the population covered by the 2024 version of the WHO's hepatitis B prevention and treatment guidelines and the Chinese antiviral treatment guidelines].","authors":"B Q Wang, S Shan, Y Y Kong, X N Wu, J L Zhou, Y M Sun, S Y Chen, H Wang, X Q Xu, S Xia, J D Jia, H You","doi":"10.3760/cma.j.cn501113-20240421-00218","DOIUrl":"10.3760/cma.j.cn501113-20240421-00218","url":null,"abstract":"<p><p><b>Objective:</b> This study aims to compare the antiviral treatment similarities and differences in the population covered by the 2024 version of the World Health Organization's (WHO) hepatitis B prevention and treatment guidelines and the current Chinese hepatitis B prevention and treatment guidelines, so as to explore their impact on the indications for antiviral therapy in Chinese patients with chronic hepatitis B (CHB). <b>Methods:</b> The information of patients with chronic hepatitis B virus infection who did not receive antiviral treatment was collected through the registration database of the China Clinical Research Platform for Hepatitis B Elimination. Descriptive statistics were conducted on the demographic, blood, biochemical, and virological levels of patients according to the treatment recommendations of the two versions of the guidelines. The Mann-Whitney U test and χ2 test were used to compare the differences and proportional distribution of the treatment populations covered by the two guidelines. The χ2 test was used to analyze the coverage rate of different antiviral treatment indications. <b>Results:</b> A total of 21,134 CHB patients without antiviral treatment were enrolled. 69.4% of patients met the 2024 versions of the WHO guidelines' recommendations. 85.0% of patients met the current Chinese hepatitis B prevention and treatment guidelines. The WHO guidelines for antiviral therapy indications were met in younger patients with higher levels of ALT, AST, and APRI scores, as well as greater proportion of patients with higher viral loads (P<0.001). The WHO guidelines recommended a cut-off value of APRI>0.5, which raised the proportion of patients on antiviral therapy from 6.6% to 30.9%. 45.7% of patients met the antiviral indications for HBV DNA >2000 IU/ml with abnormal transaminase (ALT>30 U/L for males and ALT>19 U/L for females). The reduced APRI diagnostic cut-off value and ALT treatment threshold had further increased the treatment coverage rate by 91.6% in patients with chronic HBV infection in line with the 2024 versions of WHO guidelines. <b>Conclusion:</b> The reduction of the APRI diagnostic cut-off value and the ALT treatment threshold, based on the current hepatitis B guidelines of China, will further improve the treatment coverage of CHB patients.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 6","pages":"525-531"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on detection techniques for effective albumin concentration].","authors":"M Q Li, Y D Ge, W Xie","doi":"10.3760/cma.j.cn501113-20240308-00122","DOIUrl":"10.3760/cma.j.cn501113-20240308-00122","url":null,"abstract":"<p><p>Hypoalbuminemia is one of the important clinical features of decompensated cirrhosis. As the disease progresses, not only does the total albumin concentration decrease, but so does the proportion of albumin that remains structurally and functionally intact. The structural and functional integrity of albumin is essential for its normal physiological role in the body. This led to the concept of \"effective albumin concentration,\" which may be much lower than the total albumin concentration routinely measured clinically in patients with advanced cirrhosis. Liquid chromatography-tandem mass spectrometry, and electron paramagnetic resonance (EMR) are emerging technologies for effective albumin concentration detection, showing promising clinical application prospects, but research in patients with cirrhosis is still in the preliminary stage. Therefore, this article will comprehensively summarize the latest research on the aspects of effective albumin detection methods, liquid chromatography-tandem mass spectrometry, and electron paramagnetic resonance, as well as their applications.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 6","pages":"493-496"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Characteristics of liver volume and pathological changes with different stages of liver fibrosis in chronic liver disease].","authors":"T T Zhu, Z X Li, J Yuan, K Huang, G F Chen, R F Guo, Z M Zhao, C H Liu","doi":"10.3760/cma.j.cn501113-20231219-00286","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20231219-00286","url":null,"abstract":"<p><p><b>Objective:</b> To measure the overall and lobulated volume of the liver with different degrees of liver fibrosis and to further observe pathological changes such as liver microvasculature, hepatocyte apoptosis, and regeneration in order to understand the macroscopic volume changes of the liver during liver fibrosis and its relationship with liver tissue microscopic pathology in patients with chronic liver disease. <b>Methods:</b> 53 patients with chronic hepatitis B, alcoholic fatty liver disease, autoimmune liver disease, nonalcoholic fatty liver disease, and drug-induced chronic liver disease who underwent both liver biopsy tissue and abdominal magnetic resonance imaging were collected. Patients were divided into early (F1-2), middle (F3-4), and late (F5-6) in accordance with the Ishak fibrosis stage and Masson stain. The liver and spleen volumes were measured using ITK-SNAP software. CD31 immunohistochemical staining was used to reflect intrahepatic angiogenesis. Ki67 and HNF-4α multiplex immunohistochemical staining were used to reflect hepatocyte regeneration. GS staining was used to determine parenchymal extinction lesions. TUNEL staining was used to observe hepatocyte apoptosis. Spearman correlation analysis was used to analyze the relationship between liver volume changes and liver histopathological changes. <b>Results:</b> As liver fibrosis progressed, the total liver volume and right lobe liver volume gradually decreased (<i>P</i><0.05), while the spleen volume gradually increased (<i>P</i><0.05). The expression of CD31 and GS gradually increased (<i>P</i><0.05), and the expression of Ki67 first increased and then decreased (<i>P</i><0.05). The positivity rate of CD31 was negatively correlated with the right lobe liver volume (<i>r</i>=-0.609, <i>P</i><0.001) and the total liver volume (<i>r</i>=-0.363, <i>P</i>=0.017). The positivity rate of Ki67 was positively correlated with the right lobe liver volume (<i>r</i>=0.423, <i>P</i>=0.018), while the positivity rate of apoptotic cells was significantly negatively correlated with the total liver volume (<i>r</i>=-0.860, <i>P</i><0.001). The positivity rate of GS was negatively correlated with the right lobe liver volume (<i>r</i>=-0.440, <i>P</i>=0.002), and the number of PELs was negatively correlated with RV (<i>r</i>=-0.476, <i>P</i>=0.013). The CD31 positive staining area was negatively correlated with the Ki67 positive staining area(<i>r</i>=-0.511, <i>P</i>=0.009). <b>Conclusion:</b> As liver fibrosis progresses, patients with chronic liver disease have a depletion in total liver volume and right lobe liver volume, and this is mainly in correlation with fewer liver cells and liver tissue microvasculature disorders.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 6","pages":"517-524"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical management of thrombocytopenia in cirrhosis].","authors":"J P Li, Y Tan, H Sun, G Q Lin, B B Chen, Y Wu, Z W Xie, Y P Wang, A Q Lu, Y J Guan","doi":"10.3760/cma.j.cn501113-20240326-00158","DOIUrl":"https://doi.org/10.3760/cma.j.cn501113-20240326-00158","url":null,"abstract":"<p><p>Thrombocytopenia is one of the common complications of cirrhotic patients, which can induce an increasing bleeding risk and closely correlate with bleeding following invasive procedures. Consequently, how to respond to thrombocytopenia is crucial for improving the prognosis of patients with cirrhosis. This article reviews the main mechanisms of cirrhosis concurrent with thrombocytopenia, as well as the corresponding clinical management strategies.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 6","pages":"489-492"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[New targets for the prevention and treatment of cirrhotic portal vein thrombosis].","authors":"Y W Wang, H G Ding","doi":"10.3760/cma.j.cn501113-20240229-00100","DOIUrl":"10.3760/cma.j.cn501113-20240229-00100","url":null,"abstract":"<p><p>Portal vein thrombosis (PVT) is divided into cirrhotic and non-cirrhotic PVTs. The incidence rate of PVT varies greatly among different clinical stages of cirrhosis, with an overall incidence rate of about 13.92%, and the prevalence of cirrhotic PVT following splenectomy is as high as 60%. The pathogenesis of cirrhotic PVT is still unclear. However, the activation of Janus kinase/signal transduction and activator transcription signaling pathways, the rise in the expression of von Willebrand factor, and the gut microbiota along with its metabolite trimethylamine-N-oxide play an important role in the injury of vascular endothelial cells and the formation of PVT in cirrhosis. Therefore, these could be a new target for cirrhotic PVT prevention and treatment.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 6","pages":"484-488"},"PeriodicalIF":0.0,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}